In the latest quarter, 7 analysts provided ratings for NovoCure (NASDAQ:NVCR), showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 2 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 3 | 2 | 0 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $35.14, a high estimate of $42.00, and a low estimate of $30.00. This upward trend is apparent, with the current average reflecting a 20.59% increase from the previous average price target of $29.14.
Exploring Analyst Ratings: An In-Depth Overview
The analysis of recent analyst actions sheds light on the perception of NovoCure by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Emily Bodnar | HC Wainwright & Co. | Maintains | Buy | $38.00 | $38.00 |
| Jason Bednar | Piper Sandler | Raises | Overweight | $42.00 | $28.00 |
| Emily Bodnar | HC Wainwright & Co. | Raises | Buy | $38.00 | $30.00 |
| Emily Bodnar | HC Wainwright & Co. | Raises | Buy | $38.00 | $30.00 |
| Vijay Kumar | Evercore ISI Group | Raises | Outperform | $30.00 | $18.00 |
| Emily Bodnar | HC Wainwright & Co. | Maintains | Buy | $30.00 | $30.00 |
| Emily Bodnar | HC Wainwright & Co. | Maintains | Buy | $30.00 | $30.00 |
Key Insights: Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to NovoCure. This information offers a snapshot of how analysts perceive the current state of the company. Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of NovoCure compared to the broader market. Price Targets: Delving into movements, analysts provide estimates for the future value of NovoCure's stock. This analysis reveals shifts in analysts' expectations over time.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of NovoCure's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on NovoCure analyst ratings.
Unveiling the Story Behind NovoCure
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
NovoCure's Economic Impact: An Analysis
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining NovoCure's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 21.81% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: NovoCure's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -19.71%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): NovoCure's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -8.46%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): NovoCure's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -2.51%, the company may face hurdles in achieving optimal financial performance.
Debt Management: NovoCure's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.87, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
Analyst Ratings: Simplified
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Latest Ratings for NVCR
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 2022 | Loop Capital | Initiates Coverage On | Buy | |
| Feb 2022 | Oppenheimer | Upgrades | Perform | Outperform |
| Jan 2022 | Truist Securities | Upgrades | Hold | Buy |
View More Analyst Ratings for NVCR
View the Latest Analyst Ratings
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
